Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Minar

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Clinical and Translational Science|February 22, 2025
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's diseaseAbigail Samuels, Kei Irie, Tomoyuki Mizuno, et al.
Inflammatory Bowel Diseases|December 23, 2017
Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's DiseasePhillip Minar, Kimberly Jackson, Yi-Ting Tsai, et al.
Journal of Pediatrics, Perinatology and Child Health|April 25, 2024
De Novo Crohn's Disease Diagnosed in the Setting of Acute SARS-Cov-2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized PharmacokineticsMartin Varea Romo, Kishor Acharya, Nathan R Shelman, et al.
Crohn'S & Colitis 360|November 1, 2019
Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to InfliximabPhillip Minar, Christina Lehn, Yi-Ting Tsai, et al.
Inflammatory Bowel Diseases|May 20, 2020
Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD PatientsRuben J Colman, Andrea Portocarrero-Castillo, Deepika Chona, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 25, 2019
Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease PatientsKathryn Clarkston, Yi-Ting Tsai, Kimberly Jackson, et al.
Journal of Pediatric Gastroenterology and Nutrition|May 15, 2020
A Micro-longitudinal Approach to Measuring Medication Adherence in Pediatric Inflammatory Bowel DiseasesJill M Plevinsky, Lee A Denson, Jenny Hellmann, et al.
Therapeutic Drug Monitoring|June 3, 2025
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World DataKei Irie, Phillip Minar, Jack Reifenberg, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Model-informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Clinical Pharmacokinetics|August 30, 2025
Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Clinical and Translational Science|February 22, 2025
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's diseaseAbigail Samuels, Kei Irie, Tomoyuki Mizuno, et al.
Inflammatory Bowel Diseases|December 23, 2017
Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's DiseasePhillip Minar, Kimberly Jackson, Yi-Ting Tsai, et al.
Journal of Pediatrics, Perinatology and Child Health|April 25, 2024
De Novo Crohn's Disease Diagnosed in the Setting of Acute SARS-Cov-2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized PharmacokineticsMartin Varea Romo, Kishor Acharya, Nathan R Shelman, et al.
Crohn'S & Colitis 360|November 1, 2019
Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to InfliximabPhillip Minar, Christina Lehn, Yi-Ting Tsai, et al.
Inflammatory Bowel Diseases|May 20, 2020
Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD PatientsRuben J Colman, Andrea Portocarrero-Castillo, Deepika Chona, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 25, 2019
Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease PatientsKathryn Clarkston, Yi-Ting Tsai, Kimberly Jackson, et al.
Journal of Pediatric Gastroenterology and Nutrition|May 15, 2020
A Micro-longitudinal Approach to Measuring Medication Adherence in Pediatric Inflammatory Bowel DiseasesJill M Plevinsky, Lee A Denson, Jenny Hellmann, et al.
Therapeutic Drug Monitoring|June 3, 2025
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World DataKei Irie, Phillip Minar, Jack Reifenberg, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Model-informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Clinical Pharmacokinetics|August 30, 2025
Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Pageof 5